Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom. PLoS Pathog. 5:e1000590.. 2009.
HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J. 27:457-9.. 2008.
The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr. 49:196-204.. 2008.
Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. J Infect Dis. 198:470-80.. 2008.
Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response. HIV Med. 9:27-40.. 2008.
Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors. Antivir Ther. 13:771-7.. 2008.
What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? J Antimicrob Chemother. 61:705-13.. 2008.
Emergence of the H208Y mutation in the reverse transcriptase (RT) of HIV-1 in association with nucleoside RT inhibitor therapy. J Antimicrob Chemother. 59:1013-6.. 2007.
Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS. 21:447-55.. 2007.
UK HIV drug resistance database: background and recent outputs. J HIV Ther. 12:97-8.. 2007.
Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis. 192:967-73.. 2005.
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS. 19:487-94.. 2005.